Intervention Review

You have free access to this content

Quetiapine versus typical antipsychotic medications for schizophrenia

  1. Sirijit Suttajit1,*,
  2. Manit Srisurapanont1,
  3. Jun Xia2,
  4. Siritree Suttajit3,
  5. Benchalak Maneeton1,
  6. Narong Maneeton1

Editorial Group: Cochrane Schizophrenia Group

Published Online: 31 MAY 2013

Assessed as up-to-date: 28 MAR 2010

DOI: 10.1002/14651858.CD007815.pub2


How to Cite

Suttajit S, Srisurapanont M, Xia J, Suttajit S, Maneeton B, Maneeton N. Quetiapine versus typical antipsychotic medications for schizophrenia. Cochrane Database of Systematic Reviews 2013, Issue 5. Art. No.: CD007815. DOI: 10.1002/14651858.CD007815.pub2.

Author Information

  1. 1

    Chiang Mai University, Department of Psychiatry, Faculty of Medicine, Chiang Mai, Thailand

  2. 2

    The University of Nottingham, Cochrane Schizophrenia Group, Nottingham, UK

  3. 3

    Chiang Mai University, Faculty of Pharmacy, Chiang Mai, Thailand

*Sirijit Suttajit, Department of Psychiatry, Faculty of Medicine, Chiang Mai University, Chiang Mai, 50200, Thailand. sirijits@gmail.com. ssuttaji@mail.med.cmu.ac.th.

Publication History

  1. Publication Status: New
  2. Published Online: 31 MAY 2013

SEARCH

[Figure 1]
Figure 1. PRISMA flow diagram.
[Figure 2]
Figure 2. Methodological quality summary: review authors' judgements about each methodological quality item for each included study.
[Figure 3]
Figure 3. Methodological quality graph: review authors' judgements about each methodological quality item presented as percentages across all included studies.
[Analysis 1.1]
Analysis 1.1. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 1 Global state: 1. No clinical improvement.
[Analysis 1.2]
Analysis 1.2. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 2 Global state: 2a. CGI: Average CGI-S (high = poor).
[Analysis 1.3]
Analysis 1.3. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 3 Global state: 2b. CGI: Average endpoint CGI-I (high = poor).
[Analysis 1.4]
Analysis 1.4. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 4 Leaving the study early: 1. Any reason.
[Analysis 1.5]
Analysis 1.5. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 5 Leaving the study early: 2. Adverse events.
[Analysis 1.6]
Analysis 1.6. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 6 Leaving the study early: 3. Inefficacy.
[Analysis 1.7]
Analysis 1.7. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 7 Mental state: 1a. General - average score (PANSS total, high = poor).
[Analysis 1.8]
Analysis 1.8. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 8 Mental state: 1b. General - average score -short term (BPRS total, high = poor).
[Analysis 1.9]
Analysis 1.9. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 9 Mental state: 2a. Positive symptoms - average endpoint score (PANSS positive subscore, high = poor).
[Analysis 1.10]
Analysis 1.10. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 10 Mental state: 2b. Positive symptoms - average score - short term (BPRS positive subscore, high = poor).
[Analysis 1.11]
Analysis 1.11. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 11 Mental state: 3a. Negative symptoms - average endpoint score (PANSS negative subscore, high = poor).
[Analysis 1.12]
Analysis 1.12. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 12 Mental state: 3b. Negative symptoms - average score - short term (BPRS negative subscore, high = poor)).
[Analysis 1.13]
Analysis 1.13. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 13 Mental state: 3c. Negative symptoms - average score - short term (SANS total, high = poor).
[Analysis 1.14]
Analysis 1.14. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 14 Mental state: 4. General psychopathology - average endpoint score (PANSS general psychopathology subscore, high = poor).
[Analysis 1.15]
Analysis 1.15. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 15 General functioning: General - average endpoint score - long term (GAF total score, low = poor).
[Analysis 1.16]
Analysis 1.16. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 16 Quality of life: 1a. General - average endpoint score -short term (SF-36, low = poor).
[Analysis 1.17]
Analysis 1.17. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 17 Quality of life: 1b. General - average endpoint score - long term (MANSA total score, low = poor).
[Analysis 1.18]
Analysis 1.18. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 18 Quality of life: 1c. General - average change score - long term (QLS, high = poor).
[Analysis 1.19]
Analysis 1.19. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 19 Cognitive function: 1a. General - average change score - long term (Composite score, high = poor).
[Analysis 1.20]
Analysis 1.20. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 20 Cognitive function: 1b. General - average endpoint scores as defined by the original studies (low = poor).
[Analysis 1.21]
Analysis 1.21. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 21 Service use: number of participants re-hospitalised - long term.
[Analysis 1.22]
Analysis 1.22. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 22 Adverse effects: 1. General - at least one adverse effect.
[Analysis 1.23]
Analysis 1.23. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 23 Adverse effects: 2. Death.
[Analysis 1.24]
Analysis 1.24. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 24 Adverse effects: 3a. Cardiac effects - QTc prolongation - long term.
[Analysis 1.25]
Analysis 1.25. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 25 Adverse effects: 3b. Cardiac effects - abnormal ECG - short term.
[Analysis 1.26]
Analysis 1.26. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 26 Adverse effects: 3c. Cardiac effects - orthostatic hypotension.
[Analysis 1.27]
Analysis 1.27. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 27 Adverse effects: 3d. Cardiac effects - low blood pressure - short term.
[Analysis 1.28]
Analysis 1.28. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 28 Adverse effects: 3e. Cardiac effects - tachycardia - short term.
[Analysis 1.29]
Analysis 1.29. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 29 Adverse effects: 4. Central nervous system - sedation.
[Analysis 1.30]
Analysis 1.30. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 30 Adverse effects: 5a. Extrapyramidal effects - overall - short term.
[Analysis 1.31]
Analysis 1.31. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 31 Adverse effects: 5b. Extrapyramidal effects - akathisia.
[Analysis 1.32]
Analysis 1.32. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 32 Adverse effects: 5c. Extrapyramidal effects - parkinsonism.
[Analysis 1.33]
Analysis 1.33. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 33 Adverse effects: 5d. Extrapyramidal effects - dystonia.
[Analysis 1.34]
Analysis 1.34. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 34 Adverse effects: 5e. Extrapyramidal effects - tremor - short term.
[Analysis 1.35]
Analysis 1.35. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 35 Adverse effects: 5f. Extrapyramidal effects - scale measured (dichotomous data) - long term.
[Analysis 1.36]
Analysis 1.36. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 36 Adverse effects: 5g. Extrapyramidal effects - scale measured (continuous data, high=poor).
[Analysis 1.37]
Analysis 1.37. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 37 Adverse effects: 6a. Prolactin associated side effects.
[Analysis 1.38]
Analysis 1.38. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 38 Adverse effects: 6b. Prolactin - Hyperprolactinemia.
[Analysis 1.39]
Analysis 1.39. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 39 Adverse effects: 6c. Prolactin level - average level in ng/mL.
[Analysis 1.40]
Analysis 1.40. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 40 Adverse effects: 7a. Weight gain (as defined by the original studies).
[Analysis 1.41]
Analysis 1.41. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 41 Adverse effects: 7b. Weight gain - average weight in kg..
[Analysis 1.42]
Analysis 1.42. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 42 Adverse effects: 8. decreased white blood cell count - short term.
[Analysis 1.43]
Analysis 1.43. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 43 Sensitivity analysis (skewed data excluded), Mental state: 1. General - average endpoint score (PANSS total, high = poor).
[Analysis 1.44]
Analysis 1.44. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 44 Sensitivity analysis (skewed data excluded), Mental state: 2. Negative symptoms - average endpoint score (PANSS negative subscore, high=poor) - medium term.
[Analysis 1.45]
Analysis 1.45. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 45 Sensitivity analysis (inappropriate comparator doses excluded), Mental state: 1: General- average endpoint score (PANSS total, high=poor).
[Analysis 1.46]
Analysis 1.46. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 46 Sensitivity analysis (inappropriate comparator doses excluded), Mental state: 2: Positive symptoms- average endpoint score (PANSS positive subscore, high = poor).
[Analysis 1.47]
Analysis 1.47. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 47 Sensitivity analysis (inappropriate comparator doses excluded), Mental state: 3: Negative symptoms- average endpoint score (PANSS negative subscore, high = poor).
[Analysis 1.48]
Analysis 1.48. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 48 Senstivity analysis (high attrition rate data excluded), Mental state: 1: General - average score (PANSS total, high = poor).
[Analysis 1.49]
Analysis 1.49. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 49 Sensitivity analysis (high attrition rate data excluded), Mental state: 2. Positive symptoms - average endpoint score (PANSS positive subscore, high = poor).
[Analysis 1.50]
Analysis 1.50. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 50 Sensitivity analysis (high attrition rate data excluded), Mental state: 3. Negative symptoms - average endpoint score (PANSS negative subscore, high = poor).
[Analysis 1.51]
Analysis 1.51. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 51 Senstivity analysis (completer data only), Mental state: 1: General - average score (PANSS total, high=poor).
[Analysis 1.52]
Analysis 1.52. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 52 Sensitivity analysis (completer data only), Mental state: 2. Positive symptoms - average endpoint score (PANSS positive subscore, high = poor).
[Analysis 1.53]
Analysis 1.53. Comparison 1 QUETIAPINE versus TYPICAL ANTIPSYCHOTICS, Outcome 53 Sensitivity analysis (completer data only), Mental state: 3. Negative symptoms - average endpoint score (PANSS negative subscore, high = poor).